BCL6 and diffuse large B-cell lymphoma: This is consistent with reports indicating that patients with BCL6 DHL are less likely immunophenotypically GCB, clinically aggressive, characterized by poor OS, and that the “ABC DLBCL is associated with substantially worse outcomes when treated with standard chemoimmunotherapy”, unlike their GCB peers with better therapeutic outcomes [14,24].